PI3K/AKT/mTOR Pathway in Ovarian Cancer Treatment: Are We on the Right Track?

Gasparri, Maria Luisa; Bardhi, Erlisa; Ruscito, Ilary; Papadia, Andrea; Farooqi, Ammad Ahmad; Marchetti, Claudia; Bogani, Giorgio; Ceccacci, Irene; Mueller, Michael; Benedetti Panici, Pierluigi (2017). PI3K/AKT/mTOR Pathway in Ovarian Cancer Treatment: Are We on the Right Track? Geburtshilfe und Frauenheilkunde, 77(10), pp. 1095-1103. Thieme 10.1055/s-0043-118907

[img]
Preview
Text
s-0043-118907 29093603.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (151kB) | Preview

The high recurrence rate and the low overall survival in ovarian cancer suggest that a more specific therapeutic approach in addition to conventional treatment is required. Translational and clinical research is investigating new molecular targets in order to find an alternative way to affect tumor growth and to minimize the overlap of toxicity of antiblastic agents. Given its implication in many cellular activities including regulation of cell growth, motility, survival, proliferation, protein synthesis, autophagy, transcription, as well as angiogenesis, PI3K/AKT/mTOR is one of the most investigated intracellular signaling pathways. A dis-regulation of this pathway has been shown in several tumors, including ovarian cancer. In this setting, mTor proteins represent a potential target for inhibitors, which could ultimately play a pivotal role in counteracting cellular proliferation. Recently, mTor inhibitors have been approved in the treatment of pancreatic neuroendocrine tumors, mantle cell lymphoma and renal cancer. Clinical trials have assessed the safety of these drugs in ovarian cancer patients. Ongoing phase I and II studies are evaluating the oncologic outcome of mTor inhibitor treatment and its effect in combination with conventional chemotherapy and target agents.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Gynaecology

UniBE Contributor:

Papadia, Andrea and Mueller, Michael

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0016-5751

Publisher:

Thieme

Language:

English

Submitter:

Monika Zehr

Date Deposited:

22 Feb 2018 16:00

Last Modified:

26 Oct 2019 01:29

Publisher DOI:

10.1055/s-0043-118907

PubMed ID:

29093603

Uncontrolled Keywords:

PI3K/AKT/mTOR everolimus mTOR inhibitors ovarian cancer target therapy temsirolimus

BORIS DOI:

10.7892/boris.111003

URI:

https://boris.unibe.ch/id/eprint/111003

Actions (login required)

Edit item Edit item
Provide Feedback